BC Extra | Jan 17, 2020
Tools & Techniques

EPO decision strengthens UC’s CRISPR patent position in Europe as Editas looks to Cas9 alternatives

A decision at the European Patent Office has confirmed that the CRISPR IP landscape is going to look much different in Europe than it does in the U.S., contributing to the growing complexity of global...
BC Extra | Dec 11, 2019
Tools & Techniques

Editas shows better gene editing using Cas9 alternative for sickle cell, thalassemia

Editas is using an alternative to Cas9 to develop a differentiated sickle cell and β thalassemia CRISPR gene therapy. Preclinical data presented Monday at ASH suggest that ex vivo gene editing could be more effective...
BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BC Extra | Nov 19, 2019
Clinical News

Vertex, CRISPR show early benefits with therapy, but longer term data are needed to show how it stacks up

Vertex and partner CRISPR Therapeutics showed sustained benefits in the first two patients treated with their CTX001, but longer term data will be needed to understand how the ex vivo CRISPR therapy stacks up against...
BC Extra | Nov 7, 2019
Clinical News

First U.S. clinical CRISPR data give early safety signal for ex vivo editing

CRISPR cleared its earliest safety hurdle with the first clinical data on the gene editing technology in the U.S., but it's still too early to tell whether that safety signal will persist and apply to...
BC Innovations | Nov 5, 2019
Product Development

Preprint study renews cancer fears for CRISPR-based therapies

CRISPR therapeutics companies have been quick to bounce back from each of the gene editing technology’s safety concerns originating from preprint publications in the past two and a half years, but a new paper adds...
BC Extra | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

Inhaled drug delivery platform company Vectura Group plc (LSE:VEC) hired Will Downie as CEO and executive director, effective Nov. 7. CFO Paul Fry has been serving as interim CEO since James Ward-Lilley stepped down in...
BC Extra | Oct 21, 2019
Preclinical News

Liu describes new CRISPR tech, co-founds company to develop it

The latest gene editing technology to emerge from the lab of base editing pioneer David Liu can correct disease-causing mutations without making double-stranded DNA breaks, and without relying on a cell's natural DNA damage repair...
BC Extra | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

Editas licenses MaxCyte tech to develop engineered cell medicines  Editas Medicine Inc. (NASDAQ:EDIT) licensed non-exclusive clinical and commercial rights to Flow Electroporation technology and ExPERT instruments from MaxCyte Inc. (LSE:MXCT) to develop engineered cell medicines,...
BioCentury | Sep 10, 2019
Emerging Company Profile

Trucode: advancing nuclease-free, viral vector-independent gene therapy

After bouncing around in several different companies, Peter Glazer’s peptide nucleic acid gene editing technology is getting another shot at development with the launch of Trucode. This time around, the technology is more advanced and...
Items per page:
1 - 10 of 213
BC Extra | Jan 17, 2020
Tools & Techniques

EPO decision strengthens UC’s CRISPR patent position in Europe as Editas looks to Cas9 alternatives

A decision at the European Patent Office has confirmed that the CRISPR IP landscape is going to look much different in Europe than it does in the U.S., contributing to the growing complexity of global...
BC Extra | Dec 11, 2019
Tools & Techniques

Editas shows better gene editing using Cas9 alternative for sickle cell, thalassemia

Editas is using an alternative to Cas9 to develop a differentiated sickle cell and β thalassemia CRISPR gene therapy. Preclinical data presented Monday at ASH suggest that ex vivo gene editing could be more effective...
BC Extra | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

Sanofi (Euronext:SAN; NASDAQ:SNY) said Muzammil Mansuri, EVP, head of strategy and business development, will retire at the end of the month. His responsibilities will be divided between Alban de La Sablière, head of business development,...
BC Extra | Nov 19, 2019
Clinical News

Vertex, CRISPR show early benefits with therapy, but longer term data are needed to show how it stacks up

Vertex and partner CRISPR Therapeutics showed sustained benefits in the first two patients treated with their CTX001, but longer term data will be needed to understand how the ex vivo CRISPR therapy stacks up against...
BC Extra | Nov 7, 2019
Clinical News

First U.S. clinical CRISPR data give early safety signal for ex vivo editing

CRISPR cleared its earliest safety hurdle with the first clinical data on the gene editing technology in the U.S., but it's still too early to tell whether that safety signal will persist and apply to...
BC Innovations | Nov 5, 2019
Product Development

Preprint study renews cancer fears for CRISPR-based therapies

CRISPR therapeutics companies have been quick to bounce back from each of the gene editing technology’s safety concerns originating from preprint publications in the past two and a half years, but a new paper adds...
BC Extra | Oct 30, 2019
Company News

Management tracks: Vectura, Editas, Assembly, Camp4, Tempus, Passage Bio, Boundless Bio and Prometheus

Inhaled drug delivery platform company Vectura Group plc (LSE:VEC) hired Will Downie as CEO and executive director, effective Nov. 7. CFO Paul Fry has been serving as interim CEO since James Ward-Lilley stepped down in...
BC Extra | Oct 21, 2019
Preclinical News

Liu describes new CRISPR tech, co-founds company to develop it

The latest gene editing technology to emerge from the lab of base editing pioneer David Liu can correct disease-causing mutations without making double-stranded DNA breaks, and without relying on a cell's natural DNA damage repair...
BC Extra | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

Editas licenses MaxCyte tech to develop engineered cell medicines  Editas Medicine Inc. (NASDAQ:EDIT) licensed non-exclusive clinical and commercial rights to Flow Electroporation technology and ExPERT instruments from MaxCyte Inc. (LSE:MXCT) to develop engineered cell medicines,...
BioCentury | Sep 10, 2019
Emerging Company Profile

Trucode: advancing nuclease-free, viral vector-independent gene therapy

After bouncing around in several different companies, Peter Glazer’s peptide nucleic acid gene editing technology is getting another shot at development with the launch of Trucode. This time around, the technology is more advanced and...
Items per page:
1 - 10 of 213